Development of room temperature stable formulation of formoterol fumarate/beclomethasone HFA pMDI

Indian Journal of Pharmaceutical Sciences

Volumn 71, Issue 6, 2009, Pages 713-715

  Purohit, D ^a   Trehan, A ^a   Arora, V ^a  

^a Ranbaxy Laboratories   (India)

Author keywords

Aerosols; Delivered dose uniformity; Deposition of emitted dose; Impinger

Indexed keywords

BECLOMETASONE DIPROPIONATE; EXCIPIENT; FLUORINATED HYDROCARBON; FORMOTEROL FUMARATE; MACROGOL; POVIDONE; TETRAFLUOROETHYLENE;

AEROSOL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; METERED DOSE INHALER; PARTICLE SIZE; PREDICTION; ROOM TEMPERATURE; SUSPENSION;

EID: 77249152245     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Purewal T. Formulation of metered dose inhalers, Metered dose inhalers technology, Buffalo Grove: Interpharm Press; 1998, p. 1-8.
2. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFAformulations. Int J Pharm 1999;186:13-30.
3. Hickey AJ. Inhalation Aerosols, Physical and Biological Basis for Therapy, 2nd ed. In; Lenfant C. Editors. Lung Biology in Health and Disease. Vol.221. Boca Raton: In-forma Health Care; 2007.
4. Murnane D, Martin GP, Marriott C. Investigations into the Formulation of Metered Dose Inhalers of Salmeterol Xinafoate and Fluticasone Propionate Microcrystals. Pharm Res 2008;25:2283-2291